Exercise Intervention for Lesbian, Gay, Bisexual, and Transgender Cancer Survivors
针对女同性恋、男同性恋、双性恋和变性癌症幸存者的运动干预
基本信息
- 批准号:9512855
- 负责人:
- 金额:$ 16.61万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-17 至 2020-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAdultAftercareAnxietyAreaAwardBehaviorBiologicalC-reactive proteinCancer ControlCancer Control ResearchCancer PatientCancer SurvivorCaringClinicClinicalClinical TrialsCompetenceDiscriminationDistressEnvironmentExerciseFacultyFeasibility StudiesFundingFutureGaysGoalsHealthHeterosexualsHome environmentHydrocortisoneInflammationInstructionInterventionIntervention StudiesIntervention TrialK-Series Research Career ProgramsLesbianLesbian Gay BisexualLinkMalignant NeoplasmsMedical OncologistMentorsMethodsMinorityMoodsMorbidity - disease ratePatient Self-ReportPersonal SatisfactionPersonsPhasePopulationPositioning AttributePrevalencePsyche structurePsychologistQuestionnairesRandomizedReportingResearchRiskSerum amyloid A proteinSocial supportStandardizationStressSurvivorsTestingTimeTrainingTraining ProgramsUnderserved PopulationUnited StatesUniversitiesWalkingWorkactigraphyanticancer researcharmbasebiopsychosocialcancer carecancer diagnosiscancer therapycancer typecareercareer developmentcommunity interventiondesignexercise interventionexperiencehealth disparityimprovedinnovationmembermortalitynoveloncologyphase II trialpost interventionpsychologicpsychological distresspublic health relevanceresponsestrength trainingtransgendervirtual
项目摘要
DESCRIPTION (provided by applicant): Prevalence of cancer is up to 2.1 times higher among lesbian, gay, bisexual, and transgender (LGBT) persons than heterosexuals, yet LGBT cancer survivors are virtually invisible in cancer research in the United States. This invisibility, as wel as real and expected discrimination, leads LGBT cancer patients and survivors to experience 1.7 times higher rates of psychological distress than heterosexual survivors. Given these rates of distress, the unique sociocultural factors acting on LGBT survivors, and the fact that distress is linked with increased cancer-related morbidity and mortality, tailored interventions to reduce distress among LGBT cancer survivors are needed. Our preliminary research shows that care partners of LGBT survivors want to be included in interventions to support survivors and that social support is strongly linked to psychological distress among LGBT adults. Our novel dyadic framework incorporates support from care partners and a standardized exercise intervention, Exercise for Cancer Patients (EXCAP(c)(r), a 6 week, home-based progressive walking and resistance training program), and may be effective in reducing distress among LGBT survivors. In this K07 Career Development Award application, Dr. Charles Kamen, a clinical psychologist with a background in health disparities and dyadic intervention research, proposes to conduct a Phase II RCT randomizing 70 LGBT cancer survivors (all cancer types, 1-24 months post treatment) plus their 70 care partners (broadly defined) to: Arm 1, a novel, partner-assisted version of EXCAP(c)(r) (called EXCAP-PA), in which both survivors and care partners will receive EXCAP(c)(r) materials and instruction together, or Arm 2, a survivor-only version of EXCAP(c)(r), i which only the LGBT cancer survivor will receive EXCAP(c)(r) materials. The overall hypothesis of this study is that among LGBT survivors, EXCAP-PA, incorporating care partner support, will be more efficacious than survivor-only EXCAP(c)(r) in improving biopsychosocial aspects of distress. Dr. Kamen is well positioned as a junior faculty member in an exceptional environment at the University of Rochester. He needs additional training in three core competency areas in order to launch an independent research career: 1) clinical trials for LGBT health, 2) integration of biological endpoints, and 3) design of exercise interventions. His mentors have over 30 years of experience conducting cancer control intervention trials and include: Dr. Karen Mustian, PEAK Lab Director and exercise oncology expert; Dr. Gary Morrow, Director of Cancer Control research; Dr. Kathi Heffner, psychoneuroimmunologist; Dr. Deborah Bowen, community intervention expert; and advisors Dr. Supriya Mohile, medical oncologist; Dr. James McMahon, dyadic intervention expert; and Dr. Charles Heckler, biostatistician. The career development goals and protected time provided by this training award will prepare Dr. Kamen to become an expert in cancer-related health disparities and dyadic interventions for LGBT cancer survivors and care partners. Further, if successful, this study will address a critical disparity (distress) n the underserved population of LGBT survivors.
描述(由申请人提供):女同性恋、男同性恋、双性恋和跨性别者 (LGBT) 的癌症患病率比异性恋者高 2.1 倍,但 LGBT 癌症幸存者在美国的癌症研究中几乎不可见。考虑到这些痛苦发生率、作用于 LGBT 幸存者的独特社会文化因素以及事实上,痛苦与癌症相关发病率和死亡率的增加有关,因此需要采取量身定制的干预措施来减少 LGBT 癌症幸存者的痛苦,我们的初步研究表明,LGBT 幸存者的护理伙伴希望参与支持幸存者的干预措施,并且社会支持是必要的。与 LGBT 成年人的心理困扰密切相关。我们的新型二元框架得到了护理伙伴的支持,并提供了标准化运动干预措施,即癌症患者运动(EXCAP(c)(r),一项为期 6 周的家庭渐进式步行和阻力训练计划)。 ,并且可能有效在这份 K07 职业发展奖申请中,拥有健康差异和二元干预研究背景的临床心理学家 Charles Kamen 博士建议开展一项 II 期随机对照试验,随机抽取 70 名 LGBT 癌症幸存者(所有癌症类型、治疗后 1-24 个月)加上他们的 70 个护理合作伙伴(广义): 第 1 组,EXCAP(c)(r) 的新型合作伙伴辅助版本(称为 EXCAP-PA),其中幸存者和护理伙伴将一起收到 EXCAP(c)(r) 材料和指导,或第 2 组,仅幸存者版本的 EXCAP(c)(r),其中只有 LGBT 癌症幸存者才会收到 EXCAP(本研究的总体假设是,在 LGBT 幸存者中,结合护理伙伴支持的 EXCAP-PA 在改善生物心理社会方面的痛苦方面将比仅针对幸存者的 EXCAP(c)(r) 更有效。卡门博士是作为罗切斯特大学的一名初级教员,他需要在三个核心能力领域接受额外的培训,才能开展独立的研究生涯:1) LGBT 健康的临床试验,2) 生物终点的整合, 3) 运动干预设计。他的导师拥有超过 30 年的癌症控制干预试验经验,其中包括:PEAK 实验室主任、运动肿瘤学专家 Karen Mustian 博士;癌症控制研究主任 Gary Morrow 博士;凯西·赫夫纳 (Kathi Heffner),心理神经免疫学家;黛博拉·鲍文 (Deborah Bowen) 博士,医学肿瘤学家;詹姆斯·麦克马洪 (James McMahon) 博士,生物统计学家。该培训奖将使 Kamen 博士成为癌症相关健康差异和 LGBT 癌症幸存者和护理合作伙伴双元干预方面的专家。该研究将解决服务不足的 LGBT 幸存者群体中的严重差异(困境)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles Stewart Kamen其他文献
Charles Stewart Kamen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles Stewart Kamen', 18)}}的其他基金
A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors
对免疫检查点抑制剂有持久反应的晚期癌症患者的多机构生存研究
- 批准号:
10714336 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别:
The Science of Cancer Health Equity for Sexual and Gender Minority Communities
性和性别少数群体的癌症健康公平科学
- 批准号:
10749970 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别:
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
免疫检查点抑制剂治疗 (DiRECT) 结果的差异:在社区肿瘤学环境中接受抗 PD-1/抗 PD-L1 治疗的癌症幸存者的前瞻性队列研究
- 批准号:
10883853 - 财政年份:2021
- 资助金额:
$ 16.61万 - 项目类别:
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
免疫检查点抑制剂治疗 (DiRECT) 结果的差异:在社区肿瘤学环境中接受抗 PD-1/抗 PD-L1 治疗的癌症幸存者的前瞻性队列研究
- 批准号:
10220449 - 财政年份:2021
- 资助金额:
$ 16.61万 - 项目类别:
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
免疫检查点抑制剂治疗 (DiRECT) 结果的差异:在社区肿瘤学环境中接受抗 PD-1/抗 PD-L1 治疗的癌症幸存者的前瞻性队列研究
- 批准号:
10391553 - 财政年份:2021
- 资助金额:
$ 16.61万 - 项目类别:
Exercise Intervention for Lesbian, Gay, Bisexual, and Transgender Cancer Survivors
针对女同性恋、男同性恋、双性恋和变性癌症幸存者的运动干预
- 批准号:
9112953 - 财政年份:2015
- 资助金额:
$ 16.61万 - 项目类别:
相似国自然基金
基于前景理论的ADHD用药决策过程与用药依从性内在机制研究
- 批准号:72304279
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于强化学习AI聊天机器人对MSM开展PrEP服药依从性精准干预模式探索及干预效果研究
- 批准号:82373638
- 批准年份:2023
- 资助金额:59 万元
- 项目类别:面上项目
基于HAPA理论的PCI术后患者运动依从性驱动机制与干预方案构建研究
- 批准号:72304180
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于保护动机理论的新确诊青少年HIV感染者抗病毒治疗依从性“游戏+”健康教育及作用机制研究
- 批准号:82304256
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于健康行为程式模型提升高血压患者药物依从性的干预策略构建研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Identifying and testing a tailored strategy to achieve equity in blood pressure control in PACT
确定并测试量身定制的策略,以在 PACT 中实现血压控制的公平性
- 批准号:
10538513 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别:
Social Vulnerability, Sleep, and Early Hypertension Risk in Younger Adults
年轻人的社会脆弱性、睡眠和早期高血压风险
- 批准号:
10643145 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别:
Promoting Viral Suppression through the CHAMPS+ Intervention in the Deep South
通过 CHAMPS 干预南部腹地促进病毒抑制
- 批准号:
10819823 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别:
Determinants of polymicrobial diabetic wound infections
多种微生物糖尿病伤口感染的决定因素
- 批准号:
10665269 - 财政年份:2023
- 资助金额:
$ 16.61万 - 项目类别: